Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.
暂无分享,去创建一个
Colin C Pritchard | Laura M Amendola | Gail P Jarvik | Brian H Shirts | David L Veenstra | Martha Horike-Pyne | Wylie Burke | Fuki M Hisama | G. Jarvik | W. Burke | C. Pritchard | W. Grady | F. Hisama | D. Veenstra | B. Shirts | C. Bennette | Carlos J Gallego | L. Amendola | G. Guzauskas | William M Grady | Caroline S Bennette | Greg Guzauskas | M. Horike-Pyne | M. Horike‐Pyne
[1] G. Sanders,et al. Cost-Effectiveness in Health and Medicine , 2016 .
[2] E. Adang,et al. Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] I. Frayling,et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. , 2014, Health technology assessment.
[4] Joshua T. Cohen,et al. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. , 2014, The New England journal of medicine.
[5] H. Hampel. NCCN increases the emphasis on genetic/familial high-risk assessment in colorectal cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[6] Kristen J. Vogel,et al. The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing , 2014, Journal of Genetic Counseling.
[7] Pablo Lapunzina,et al. Impact of NGS in the medical sciences: Genetic syndromes with an increased risk of developing cancer as an example of the use of new technologies , 2013, Genetics and molecular biology.
[8] Kenneth Offit,et al. Translating genomics in cancer care. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] Marc S. Williams,et al. Impact of age cutoffs on a lynch syndrome screening program. , 2013, Journal of oncology practice.
[10] L. Aaltonen,et al. Prevalence of germline PTEN, BMPR1A, SMAD4, STK11, and ENG mutations in patients with moderate-load colorectal polyps. , 2013, Gastroenterology.
[11] J. Stockman,et al. Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer: A Cost-Effectiveness Analysis , 2013 .
[12] Colin C Pritchard,et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. , 2012, The Journal of molecular diagnostics : JMD.
[13] J. Lupski,et al. Human genome sequencing in health and disease. , 2012, Annual review of medicine.
[14] O. Dekkers,et al. Survival of MUTYH-Associated Polyposis Patients With Colorectal Cancer and Matched Control Colorectal Cancer Patients , 2010, Journal of the National Cancer Institute.
[15] Heather Hampel,et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer , 2010, Genetics in Medicine.
[16] Z. Szentirmay,et al. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome , 2009, Human mutation.
[17] Monica R McClain,et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome , 2009, Genetics in Medicine.
[18] P. Møller,et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer) , 2007, Journal of Medical Genetics.
[19] K. Kinzler,et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. , 2007, Journal of the National Cancer Institute.
[20] W. Frankel,et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. , 2006, Cancer research.
[21] H. Morreau,et al. Diagnostic Approach and Management of Lynch Syndrome (Hereditary Nonpolyposis Colorectal Carcinoma): A Guide for Clinicians , 2006, CA: a cancer journal for clinicians.
[22] W. Frankel,et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.
[23] Il-Jin Kim,et al. [Hereditary colorectal cancer]. , 2005, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
[24] M. Weinstein,et al. When does quality-adjusting life-years matter in cost-effectiveness analysis? , 2004, Health economics.
[25] Sudhir Srivastava,et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.
[26] G. Petersen,et al. AGA technical review on hereditary colorectal cancer and genetic testing. , 2001, Gastroenterology.
[27] H. Vasen. Clinical diagnosis and management of hereditary colorectal cancer syndromes. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] L. Aaltonen,et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.